Cure My Disease

Don't miss your cure!

 Log in / Sign up

A 10-Minute chat in the Doctor's office could teach teens to save a life

NCT ID NCT07797933

Prevention Sponsor: Boston Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This trial tests whether a short educational session during a routine primary care visit can help young people aged 13 to 26 understand overdose risks, recognize an overdose, and respond with naloxone. Providers in the intervention group deliver the education and offer naloxone access, while a control group receives usual care. The study enrolls 24 providers and 624 youth across three community health centers. Researchers measure whether providers deliver the education consistently and whether youth gain knowledge and confidence in overdose response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Brief youth overdose prevention education, including naloxone access facilitation
What this could lead to
If effective, this brief education could become a standard part of pediatric primary care, helping youth avoid overdoses and save lives.
What could go wrong
The trial is relatively small and measures knowledge and fidelity, not actual overdose rates, so real-world impact remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 648 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Providers: * Physicians and advance practice providers (nurse practitioners and physician assistants) within Pediatric Primary Care and Family Medicine at Boston Medical Center, NeighborHealth, and South Boston Community Health Center * ≥ 1 clinic session per week Youth: * Ages 13 - 26 * Scheduled for a CPE or follow-up clinical appointment with a provider who is participating in the trial * English speaking Exclusion Criteria: Providers: * Participated as an intervention provider in the R61 pilot RCT (H-45731) * Participated in the Community Advisory Board that assisted in the development of the intervention (H-45388) Youth: * Caregivers of youth ages 13-17 unable to provide informed consent or are not English speaking * Cognitive limitation or intellectual disability that in the opinion of their provider would not be able to complete the requirements of the research * Young adults ages 18-26 with a legal guardian * Any medical/psychiatric condition that causes acute distress and requires emergency evaluation * Under legal custody of the Department of Children and Families (DCF) * Participated in the intervention arm of the R61 pilot RCT (H-45731)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overdose are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Drug Overdose poisoning

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Overdose

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Boston Medical Center

    Boston, Massachusetts, 02118, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.